Strive offers thousands of patient-tailored, outcome-oriented compounded formulations
In June 2024, for instance, Lilly published detailed results from its Phase II SYNERGY-NASH study, demonstrating that tirzepatide could potentially improve fibrosisliver scarringin patients with metabolic dysfunction-associated steatohepatitis (MASH)
For NAD+, the strongest evidence is in metabolic disease, addiction recovery, and early neurodegenerative models
Historically, the development of appetite-suppressing drugs has focused on targeting receptors or transporters of neurotransmitters and neuromodulators released by neurons involved in central feeding regulation
Yes, you can and should eat carbs on GLP-1s
Medicinal plants as alternative sources of therapeutics against multidrug resistant pathogenic microorganisms based on their antimicrobial potential and synergistic properties